An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders.
Pharmacovigilance databases are usually used to detect new potential signals that are relevant for drug safety. They are seldom used for explanatory purposes, e.g. to understand the mechanisms of adverse drug reactions (ADRs). The aim of the present study was to combine pharmacovigilance and pharmacodynamic data to investigate the association between dopamine D2, serotonin 5HT2A, and muscarinic M1 receptor occupancy and the risks of antipsychotic drug (AP)-induced movement disorders.



First, we performed a case-noncase analysis using spontaneous reports from the World Health Organization (WHO) Global Individual Case Safety Report (ICSR) database, VigiBase®. We thus measured the risk of reporting movement disorders compared with all other ADRs [expressed as a reporting odds ratio (ROR)] for APs. Second, we performed a linear regression analysis to explore the association between the estimated risk of reporting for individual drugs and their receptor occupancy properties, for D2, 5HT2A and M1 receptors.



Compared with second-generation APs, first-generation APs were found to be significantly more associated with the reporting of movement disorders in general but also with dystonia, Parkinsonism, akathisia and tardive dyskinesia, irrespective of gender. A significant inverse correlation was found between the ROR for movement disorders and the receptor occupancy of 5HT2A [P < 0.001; R2= 0.51; slope = -0.014; 95% confidence interval (CI) (-0.029, 0.001)], M1 (P < 0.001; R2= 0.56; slope = -0.014; 95% CI (-0.028, 0.001) but not D2 dopamine (P = 0.54; R2= 0.02; slope = -0.003; 95% CI (-0.007, 0.001) receptors.



Using the example of AP-induced movement disorders, the present study underlines the value of the pharmacoepidemiological-pharmacodynamic method to explore ADR mechanisms in humans and real-life settings.
Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.|INSERM UMR 1027, Unité de Pharmacoépidémiologie, Université de Toulouse, Toulouse, France.|Faculté de Médecine et de Pharmacie, Université Nationale du Vietnam - Hanoi, Hanoi, Vietnam.
Thi Thu Ha
TT
Nguyen
Département de Pharmacologie Médicale, INSERM, U1219-Pharmacoepidemiology, Université de Bordeaux, F-33000, Bordeaux, France.
Antoine
A
Pariente
Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.|INSERM UMR 1027, Unité de Pharmacoépidémiologie, Université de Toulouse, Toulouse, France.|Département de Pharmacologie Médicale, INSERM, U1219-Pharmacoepidemiology, Université de Bordeaux, F-33000, Bordeaux, France.|CIC INSERM 1436, Université de Toulouse, Toulouse, France.|NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire, Toulouse, France.
Jean-Louis
JL
Montastruc
Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.|INSERM UMR 1027, Unité de Pharmacoépidémiologie, Université de Toulouse, Toulouse, France.|CIC INSERM 1436, Université de Toulouse, Toulouse, France.|NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire, Toulouse, France.
Maryse
M
Lapeyre-Mestre
Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.|INSERM UMR 1027, Unité de Pharmacoépidémiologie, Université de Toulouse, Toulouse, France.|Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.|CIC INSERM 1436, Université de Toulouse, Toulouse, France.
Vanessa
V
Rousseau
Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.|CIC INSERM 1436, Université de Toulouse, Toulouse, France.|NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire, Toulouse, France.
Olivier
O
Rascol
Département de Pharmacologie Médicale, INSERM, U1219-Pharmacoepidemiology, Université de Bordeaux, F-33000, Bordeaux, France.
Bernard
B
Bégaud
Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.|Département de Pharmacologie Médicale, INSERM, U1219-Pharmacoepidemiology, Université de Bordeaux, F-33000, Bordeaux, France.|Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.|CIC INSERM 1436, Université de Toulouse, Toulouse, France.|NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire, Toulouse, France.
François
F
Montastruc
D016907:Adverse Drug Reaction Reporting Systems / Q000706:statistics & numerical data; D014150:Antipsychotic Agents / Q000009:adverse effects*; D065127:Dopamine D2 Receptor Antagonists / Q000009:adverse effects*; D004409:Dyskinesia, Drug-Induced / Q000453:epidemiology*; D006801:Humans; D018727:Muscarinic Antagonists / Q000009:adverse effects*; D017891:Pharmacoepidemiology / Q000379:methods*; D060735:Pharmacovigilance; D058830:Serotonin 5-HT2 Receptor Antagonists / Q000009:adverse effects*; D014944:World Health Organization
D014150:Antipsychotic Agents; D065127:Dopamine D2 Receptor Antagonists; D018727:Muscarinic Antagonists; D058830:Serotonin 5-HT2 Receptor Antagonists
VigiBase; antipsychotic drugs; drug mechanisms; movement disorders; pharmacoepidemiology
Therapie. 2010 Sep-Oct;65(5):447-58
21144480
Int J Clin Oncol. 2009 Dec;14(6):518-24
19967488
Eur Heart J. 2005 Mar;26(6):590-7
15637086
Pharmacoepidemiol Drug Saf. 2004 Aug;13(8):519-23
15317031
Br J Pharmacol. 2015 Dec;172(24):5744-869
26650439
Harv Rev Psychiatry. 2006 May-Jun;14(3):152-64
16787887
Drug Saf. 2006;29(5):385-96
16689555
J Clin Psychiatry. 1998 Aug;59(8):403-4
9721819
Drug Saf. 1999 Feb;20(2):109-17
10082069
Am J Geriatr Psychiatry. 2009 Mar;17(3):255-63
19225277
J Nucl Med. 2015 Nov;56(11):1752-65
26383148
Eur Neuropsychopharmacol. 2015 Oct;25(10):1556-65
26256010
N Engl J Med. 2005 Sep 22;353(12):1209-23
16172203
Br J Clin Pharmacol. 2017 Mar;83(3):612-622
27687785
Acta Psychiatr Scand Suppl. 1994;380:36-40
7914046
J Clin Psychopharmacol. 2014 Jun;34(3):327-30
24561328
Br J Clin Pharmacol. 2011 Dec;72(6):905-8
21658092
Pharmacol Ther. 2010 Jan;125(1):169-79
19931306
Bioinformatics. 2010 Apr 1;26(7):985-6
20156991
Lancet. 2013 Sep 14;382(9896):951-62
23810019
J Rheumatol. 2001 May;28(5):1180-7
11361210
Pharmacopsychiatry. 2011 Sep;44(6):195-235
21969060
Br J Clin Pharmacol. 1999 Mar;47(3):329-31
10215758
Drug Intell Clin Pharm. 1987 Nov;21(11):915-20
3678067
Nat Chem Biol. 2013 Apr;9(4):232-40
23508189
Br J Pharmacol. 2015 Dec;172(24):5729-43
26650438
Arch Gen Psychiatry. 1974 Jul;31(1):58-61
4152054
Neurol Clin. 2011 Feb;29(1):127-48, viii
21172575
Synapse. 2002 Oct;46(1):32-7
12211096
Pharmacoepidemiol Drug Saf. 2005 Apr;14(4):285-6
15782397
Lancet. 2000 Oct 7;356(9237):1255-9
11072960
Nucleic Acids Res. 2016 Jan 4;44(D1):D1054-68
26464438
Drug Saf. 2001;24(10):715-25
11676300
ChemMedChem. 2007 Jun;2(6):861-73
17477341
CNS Drugs. 2009 Aug;23(8):649-59
19594194
Drug Saf. 2015 Dec;38(12):1153-68
26370106
J Clin Psychopharmacol. 2011 Aug;31(4):497-502
21694629
Trends Pharmacol Sci. 2004 Apr;25(4):186-92
15063082